Disease, Disorders, Medical Disciplines

JDRF International

aka JDRF

New York, NY


JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers in more than 100 locations throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.

Notes from the Nonprofit

JDRF is the only global organization with a strategic research plan to end T1D. Our plan ensures that there will be an ongoing stream of life-changing therapies moving from development through to commercialization that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D.

Ruling Year


Principal Officer

Mr. Derek Rapp

Main Address

26 Broadway 14th Floor

New York, NY 10004 USA


"diabetes", "diabetes research", "type 1 diabetes", T1D, JDRF





Cause Area (NTEE Code)

Specifically Named Diseases (G80)

Fund Raising and/or Fund Distribution (T12)

IRS Filing Requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2017, 2016 and 2015.
Register now

Social Media

Programs + Results

What we aim to solve New!

Add a problem overview to your profile.

Update now

Our programs

What are the organization's current programs, how do they measure success, and who do the programs serve?

SOURCE: Self-reported by organization

Artificial Pancreas



Smart Insulin



Where we workNew!

Add a map of your service areas to your profile.

Update now

Charting Impact

Five powerful questions that require reflection about what really matters - results.

SOURCE: Self-reported by organization

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

How will they know if they are making progress?

What have and haven't they accomplished so far?

JDRF's goal is a world without type 1 diabetes (T1D).

Our plan is to create a future where:
- Your blood glucose levels can be controlled automatically
- You can sleep, eat, exercise, and live as if T1D is not in your life
- T1D can be cured and is no longer present in your body
- T1D can be prevented and never threaten anyone again

In short, JDRF seeks to turn Type One into Type None.

JDRF is the only organization with a strategic research plan to end T1D. Our strategies include:

Artificial Pancreas Systems
Artificial pancreas systems will eliminate blood glucose testing and carb counting by totally automating insulin dosing, initially preventing dangerous low blood sugars and eventually ensuring ideal glucose control.

JDRF’s complications research is leading to therapies to treat and even reverse some of the debilitating, costly, and life-threatening complications caused by T1D.

JDRF’s encapsulation research will restore insulin independence for 18 months to two years by implanting newly created beta cells into a protective capsule, which eliminates the need for toxic immune suppression therapies.

Smart Insulin
Smart insulin would give those with T1D perfect blood glucose control throughout the day via a single daily dose of insulin that circulates in the bloodstream, turning on only when it is needed to lower blood sugars and turning off when it’s not needed.

Restoration is the biologic cure for T1D. It involves saving and growing new beta cells to restore the body’s normal beta cell function and restoring immune tolerance so the autoimmune attack is blocked.

JDRF’s prevention research seeks to slow or stop the progression of T1D before insulin dependence occurs. Long term, we aim to eliminate the risk of anyone developing the disease through vaccine therapies.

JDRF is focused on bringing life-changing therapies from the lab to the community by impacting every stage of the drug delivery pipeline. Working the pipeline to expedite and sustain meaningful scientific progress, made possible by our donors, is the key to delivering progressively advanced therapies. This means:

- Driving research across the entire scientific and development spectrum, from discovery in the laboratory to delivery in patients
- Collaborating with public, private, academic and corporate partners to expedite delivery of real-world solutions
- Advocating for progress that will improve lives today and lead to a cure tomorrow

JDRF is uniquely positioned to create a future without T1D. We're driving progress from advances in the lab to therapies that positively impact everyone with T1D by:

- Partnering with academia, foundations, government, and industry to leverage our research investments
- Advocating to ensure that new therapies are both available and affordable
- Managing funds efficiently, which earned JDRF its 2012 designation as one of Forbes Magazine's Top 5 charitable organizations
- Harnessing the passion of our dedicated volunteers and donors

JDRF is leading the way in establishing measurement guidelines and holding itself accountable to supporters. JDRF has developed transparent organizational goals, as well as a set of research and advocacy objectives and outcomes for the current year by which organizational success will be measured. Measurements include:

- Initiating new clinical trials for artificial pancreas systems
- Developing new approaches to encapsulating islets
- Beginning proof-of-concept clinical trials with existing islet encapsulation approaches
- Trials demonstrating slowing progression of T1D in at-risk patients
- Effectiveness of approved T2D drugs tested in T1D
- Partnering to develop new T1D biomarkers
- Congress enacts $150 million extension of Special Diabetes Program at the National Institutes of Health

JDRF funded research is driving significant advances in T1D therapies, showing us that there won't be one "eureka" moment that will cause T1D to vanish all at once. Instead, exciting and meaningful progress will come from a series of research programs across a wide variety of therapeutic approaches.

Some current measures of progress include:

- JDRF is building on the wealth of knowledge accumulated through basic research in recent years. We’re now in the exciting position of taking that research knowledge and translating it into real therapies that will make life-changing differences for those facing the daily challenges of T1D.

- Innovations driven by JDRF, such as artificial pancreas systems, treatments for T1D complications, encapsulated beta cells, and prevention therapies are beginning to advance beyond the lab. These advances have the potential to transform the lives of people with T1D and ultimately bring about a world without T1D.

- Even as we sustain our commitment to academic-discovery research, JDRF is increasingly focused on funding therapeutic human clinical trials to test the safety and efficacy of therapies and devices that can remove the burden of T1D from people’s lives as we progress toward a cure. Currently, JDRF is funding more than 50 human clinical trials.

- People with T1D are already benefitting from JDRF’s research leadership. JDRF-funded research has led directly to new significantly improved treatments, such as Lucentis, which can reverse vision loss for people with diabetic eye disease. Because of JDRF’s leadership, closed-loop artificial pancreas systems are successfully regulating blood sugar levels in people with T1D in outpatient trials and coming closer to market. And trials testing implanted beta cells using encapsulation devices to protect them from the body’s immune system, with the goal of establishing insulin independence for people with T1D, are underway with more to come soon.

JDRF's plan for progress requires more funding than we have today. JDRF funds over $100 million in T1D research each year. Currently, JDRF's ongoing research programs total more than $500 million around the world to discover and develop therapies to improve live with T1D, and eventually eliminate T1D from our lives entirely. But it is not enough. We know we can get from Type One to Type None faster by accelerating our fundraising and continuing to build momentum in T1D research. More support is crucial to creating a future where T1D is a thing of the past.

External Reviews


JDRF International

Fiscal year: Jul 01 - Jun 30

Need more info on this nonprofit?

Need more info on this nonprofit?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2016 and 2015
A Pro report is also available for this organization for $125.
Click here to view a Sample Report.


The people, governance practices, and partners that make the organization tick.

Need more info?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2016 and 2015
A Pro report is also available for this organization for $125.
Click here to see what's included.

Board Leadership Practices

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.

SOURCE: Self-reported by organization


Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?

Not Applicable


Has the board conducted a formal, written assessment of the chief executive within the past year?

Not Applicable


Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?

Not Applicable


Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?

Not Applicable


Has the board conducted a formal, written self-assessment of its performance within the past three years?

Not Applicable